Redmile Group
Latest statistics and disclosures from Redmile Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ImmunoGen, KRYS, FOLD, SRRK, Rayzebio, and represent 41.07% of Redmile Group's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$68M), IMNM (+$42M), BHVN (+$40M), ALXO (+$35M), IDYA (+$33M), SRRK (+$31M), ABT (+$29M), RGNX (+$21M), NGNE (+$18M), ISRG (+$18M).
- Started 9 new stock positions in IMNM, IDYA, NGNE, ALGN, ISRG, Science 37 Holdings, SPY, ABT, ACIU.
- Reduced shares in these 10 stocks: KRYS (-$34M), ImmunoGen (-$32M), FOLD (-$30M), ELV (-$29M), HUM (-$29M), CLDX (-$26M), DXCM (-$23M), AKRO (-$15M), PEN (-$15M), XENE (-$14M).
- Sold out of its positions in CUTR, DXCM, HUM, Neoleukin Therapeutics, Science 37 Holdings, SONX, XENE.
- Redmile Group was a net buyer of stock by $145M.
- Redmile Group has $2.8B in assets under management (AUM), dropping by 33.03%.
- Central Index Key (CIK): 0001425738
Tip: Access up to 7 years of quarterly data
Positions held by Redmile Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Redmile Group
Redmile Group holds 70 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| ImmunoGen | 17.4 | $487M | -6% | 16M | 29.65 |
|
| Krystal Biotech (KRYS) | 7.7 | $215M | -13% | 1.7M | 124.06 |
|
| Amicus Therapeutics (FOLD) | 7.5 | $210M | -12% | 15M | 14.19 |
|
| Scholar Rock Hldg Corp (SRRK) | 4.3 | $120M | +35% | 6.4M | 18.80 |
|
| Rayzebio | 4.1 | $116M | 1.9M | 62.17 |
|
|
| Augmedix (AUGX) | 3.4 | $96M | +4% | 16M | 5.85 |
|
| Deciphera Pharmaceuticals (DCPH) | 2.8 | $77M | +7% | 4.8M | 16.13 |
|
| Spdr S&p 500 Etf Tr Tr Unit (SPY) | 2.4 | $68M | NEW | 143k | 475.31 |
|
| Regenxbio Inc equity us cm (RGNX) | 2.4 | $68M | +46% | 3.8M | 17.95 |
|
| Biohaven (BHVN) | 2.2 | $62M | +178% | 1.4M | 42.80 |
|
| Zymeworks Del (ZYME) | 2.2 | $60M | +2% | 5.8M | 10.39 |
|
| Livanova SHS (LIVN) | 2.1 | $59M | +3% | 1.1M | 51.74 |
|
| Alx Oncology Hldgs (ALXO) | 1.9 | $55M | +185% | 3.7M | 14.89 |
|
| Catalent (CTLT) | 1.8 | $49M | +25% | 1.1M | 44.93 |
|
| Fate Therapeutics (FATE) | 1.8 | $49M | 13M | 3.74 |
|
|
| Pliant Therapeutics (PLRX) | 1.7 | $49M | 2.7M | 18.11 |
|
|
| Kymera Therapeutics (KYMR) | 1.7 | $46M | -2% | 1.8M | 25.46 |
|
| Immunome (IMNM) | 1.5 | $42M | NEW | 3.9M | 10.70 |
|
| Immunovant (IMVT) | 1.5 | $41M | -11% | 977k | 42.13 |
|
| Boston Scientific Corporation (BSX) | 1.4 | $40M | -10% | 693k | 57.81 |
|
| Shattuck Labs (STTK) | 1.4 | $40M | 5.6M | 7.13 |
|
|
| Celldex Therapeutics Com New (CLDX) | 1.4 | $39M | -39% | 994k | 39.66 |
|
| Beam Therapeutics (BEAM) | 1.4 | $39M | -2% | 1.4M | 27.22 |
|
| Absci Corp (ABSI) | 1.2 | $34M | 8.0M | 4.20 |
|
|
| Nurix Therapeutics (NRIX) | 1.2 | $34M | +14% | 3.3M | 10.32 |
|
| Ideaya Biosciences (IDYA) | 1.2 | $33M | NEW | 936k | 35.58 |
|
| Replimune Group (REPL) | 1.2 | $33M | -7% | 3.9M | 8.43 |
|
| Cabaletta Bio (CABA) | 1.1 | $31M | -22% | 1.4M | 22.70 |
|
| Abbott Laboratories (ABT) | 1.0 | $29M | NEW | 266k | 110.07 |
|
| Evolent Health Cl A (EVH) | 1.0 | $28M | +79% | 836k | 33.03 |
|
| Akero Therapeutics (AKRO) | 0.9 | $26M | -37% | 1.1M | 23.35 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.9 | $25M | +8% | 15M | 1.66 |
|
| Annexon (ANNX) | 0.9 | $25M | +57% | 5.5M | 4.54 |
|
| Igm Biosciences (IGMS) | 0.9 | $25M | 3.0M | 8.31 |
|
|
| Verve Therapeutics (VERV) | 0.9 | $24M | +112% | 1.7M | 13.94 |
|
| Penumbra (PEN) | 0.9 | $24M | -38% | 95k | 251.54 |
|
| 89bio (ETNB) | 0.8 | $22M | +158% | 2.0M | 11.17 |
|
| Charles River Laboratories (CRL) | 0.7 | $21M | +30% | 87k | 236.40 |
|
| Entrada Therapeutics (TRDA) | 0.7 | $19M | 1.3M | 15.09 |
|
|
| Neurogene (NGNE) | 0.7 | $18M | NEW | 947k | 19.38 |
|
| Intuitive Surgical Com New (ISRG) | 0.7 | $18M | NEW | 54k | 337.36 |
|
| Hca Holdings (HCA) | 0.6 | $18M | +167% | 66k | 270.68 |
|
| Cogent Biosciences (COGT) | 0.6 | $17M | +41% | 2.9M | 5.88 |
|
| Stryker Corporation (SYK) | 0.6 | $16M | -43% | 53k | 299.46 |
|
| Repare Therapeutics Ord (RPTX) | 0.6 | $16M | -10% | 2.1M | 7.30 |
|
| Stoke Therapeutics (STOK) | 0.5 | $14M | -32% | 2.6M | 5.26 |
|
| Align Technology (ALGN) | 0.5 | $14M | NEW | 50k | 274.00 |
|
| Gritstone Oncology Ord (GRTS) | 0.4 | $12M | -30% | 5.9M | 2.04 |
|
| Prime Medicine (PRME) | 0.4 | $12M | 1.3M | 8.86 |
|
|
| Anthem (ELV) | 0.4 | $11M | -72% | 23k | 471.56 |
|
| Allakos (ALLK) | 0.4 | $10M | -11% | 3.7M | 2.73 |
|
| Ac Immune Sa SHS (ACIU) | 0.4 | $10M | NEW | 2.0M | 5.00 |
|
| Rapt Therapeutics (RAPT) | 0.3 | $9.1M | -14% | 367k | 24.85 |
|
| Stereotaxis Com New (STXS) | 0.2 | $6.0M | -40% | 3.4M | 1.75 |
|
| Adagio Therapeutics (IVVD) | 0.2 | $5.7M | 1.4M | 3.94 |
|
|
| Science 37 Holdings Com New | 0.2 | $5.3M | NEW | 990k | 5.34 |
|
| Atara Biotherapeutics (ATRA) | 0.2 | $4.7M | +44% | 9.1M | 0.51 |
|
| Nuvation Bio Com Cl A (NUVB) | 0.2 | $4.6M | 3.0M | 1.51 |
|
|
| Lava Therapeutics Nv SHS (LVTX) | 0.1 | $3.3M | 2.1M | 1.58 |
|
|
| Medavail Holdings Com New (MDVLQ) | 0.1 | $3.1M | 692k | 4.41 |
|
|
| Xeris Pharmaceuticals (XERS) | 0.1 | $2.5M | 1.0M | 2.35 |
|
|
| Achilles Therapeutics Sponsored Ads (ACHL) | 0.1 | $1.4M | 1.6M | 0.89 |
|
|
| Allovir (ALVR) | 0.0 | $1.3M | 1.9M | 0.68 |
|
|
| Somalogic Class A Com | 0.0 | $938k | -7% | 371k | 2.53 |
|
| Invitae (NVTAQ) | 0.0 | $924k | -35% | 1.5M | 0.63 |
|
| Hookipa Pharma Inc equity (HOOK) | 0.0 | $862k | 1.1M | 0.81 |
|
|
| Alpha Teknova (TKNO) | 0.0 | $601k | -43% | 161k | 3.73 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.0 | $568k | 716k | 0.79 |
|
|
| Ventyx Biosciences (VTYX) | 0.0 | $512k | -77% | 207k | 2.47 |
|
| Atreca Cl A Com (BCEL) | 0.0 | $58k | 443k | 0.13 |
|
Past Filings by Redmile Group
SEC 13F filings are viewable for Redmile Group going back to 2010
- Redmile Group 2023 Q4 filed Feb. 14, 2024
- Redmile Group 2023 Q3 filed Nov. 14, 2023
- Redmile Group 2023 Q2 filed Aug. 14, 2023
- Redmile Group 2023 Q1 filed May 15, 2023
- Redmile Group 2022 Q4 filed Feb. 14, 2023
- Redmile Group 2022 Q3 filed Nov. 14, 2022
- Redmile Group 2022 Q2 filed Aug. 15, 2022
- Redmile Group 2022 Q1 filed May 16, 2022
- Redmile Group 2021 Q4 filed Feb. 14, 2022
- Redmile Group 2021 Q3 filed Nov. 15, 2021
- Redmile Group 2021 Q2 filed Aug. 16, 2021
- Redmile Group 2021 Q1 filed May 17, 2021
- Redmile Group 2020 Q4 filed Feb. 16, 2021
- Redmile Group 2020 Q3 filed Nov. 16, 2020
- Redmile Group 2020 Q2 filed Aug. 14, 2020
- Redmile Group 2020 Q1 filed May 15, 2020